<DOC>
	<DOCNO>NCT01753076</DOCNO>
	<brief_summary>This 48-week , randomised , multi-centre , double-blind , placebo-controlled , parallel group investigation efficacy safety intravenous ( IV ) ozanezumab ( GSK1223249 ) compare placebo subject Amyotrophic Lateral Sclerosis ( ALS ) . Following screen period four week , eligible subject randomise ( 1:1 ) receive IV placebo 15 milligram ( mg ) / kilogram ( kg ) IV ozanezumab every 2 week period 48 week follow-up visit around 14 week last infusion . A total approximately 294 eligible subject randomise approximately 37 center worldwide . The primary objective ass effect ozanezumab physical function survival ALS subject treatment period 48 week . Function measure use ALS Functional Rating Scale - Revised ( ALSFRS-R ) . Secondary objective include evaluation clinical outcome associate ALS ( respiratory function , muscle strength , progression free survival overall survival ) support primary objective . Quality life , safety , tolerability , immunogenicity pharmacokinetics ( ozanezumab riluzole ) also assess .</brief_summary>
	<brief_title>Study Ozanezumab ( GSK1223249 ) Versus Placebo Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients diagnosis familial sporadic ALS Onset muscle weakness 30 month screen visit . Slow Vital Capacity ( SVC ) least 65 % predicted gender , age , ethnicity height Screening . If riluzole , dose must stable least 28 day prior Baseline visit . Age 18 80 year inclusive . Female subject may participate nonchildbearing potential childbearing potential must agree use approve contraceptive method Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin &lt; =1.5xULN . QTc ( QTcB QTcF ) &lt; 450 millisecond ( msec ) &lt; 480 msec subject Bundle Branch Block Screening Baseline ( average triplicate ECGs ) . Patients neuromuscular disorder ( include history polio ) opinion investigator could contribute muscular atrophy weakness cause ALS Patients primary lateral sclerosis , monomelic ALS , ALS Parkinsonism dementia complex . Patients require noninvasive mechanical ventilation ( noninvasive ventilation sleep apnoea allow subject discussion Medical Monitor ) Patients diaphragmatic pacing . Presence follow clinical condition : Drug abuse alcoholism , uncontrolled hypertension , active major infectious disease , unstable psychiatric illness within 90 day Screening visit Subjects , investigator 's judgement , pose significant suicide risk . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) , positive Hepatitis B surface antigen Hepatitis C antibody test . Subjects participate clinical trial involve receipt biopharmaceutical product within 6 month prior first dose day . Exposure nonbiological experimental agent 1 month 5 halflives prior Baseline visit ( whichever longer ) . History sensitivity ozanezumab , component thereof , history allergy , opinion investigator , contraindicate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>efficacy</keyword>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>ozanezumab</keyword>
	<keyword>safety</keyword>
</DOC>